Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Surufatinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Surufatinib overview

Surufatinib (Sulanda) is a potential antineoplastic and anti-angiogenic agent. It is formulated as capsules for oral route of administration. Sulanda is indicated for the treatment of non-pancreatic neuroendocrine tumors (“NETs”).
Surufatinib is under development for the treatment of neuroendocrine tumors, solid tumors,  primary peritoneal cancer, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, lymphoma, non-rhabdomyosarcoma soft tissue sarcoma, neuroendocrine tumors of pancreatic and non-pancreatic (Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)), thyroid and gallbladder cancer, non-small cell lung cancer, extrahepatic cholangiocarcinoma, medullary thyroid cancer, metastatic biliary tract carcinoma including extrahepatic cholangiocarcinoma (EHCC), endometrial cancer, colorectal cancer, neuroendocrine carcinoma, adenocarcinoma of the gastroesophageal junction, soft tissue sarcoma, small-cell lung cancer, gastric cancer, esophageal squamous cell carcinoma, intrahepatic cholangiocarcinoma (IHCC) or gallbladder biliary carcinoma (GBC), epithelial ovarian cancer, metastatic pancreatic cancer, fallopian tube cancer and ovarian clear cell carcinoma . It is administered orally.

Hutchison MediPharma overview

Hutchison MediPharma (HMPL) carries out discovery, development and commercialization of therapeutics in oncology and autoimmune diseases. The company’s products include savolitinib, fruquintinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. It develops drug discovery technologies in molecular and cell biology, high throughput screening, genomics and informatics to support research and development projects. HMPL’s research and development programs comprise gene-targeted and cell-based screening assays, ligand-dependent screening assays and signal transduction pathway screening assays. The company’s products serve in the fields of medicinal chemistry, pharmacology, oncology, cardiovascular and respiratory diseases, and antiviral treatments. HMPL is headquartered in Pudong, China.

For a complete picture of Surufatinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.